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1. Introduction
  The prevalence of age-related bone loss is higher in 
women than in men, and in 25% to 30% of aging women 
this loss results in major orthopedic problems[1,2]. Natural 
or surgical menopause results in an initial phase of rapid 
bone loss followed by a period of slower deterioration of the 
skeleton[3,4]. This rapid phase of bone loss occurs within the 
first 10 years following the cessation of menses or surgical 
removal of the ovaries. The ovarian hormone deficiency 
associated with menopause results in increased rate of bone 
turnover and causes an imbalance between resorption and 
formation, and thereby accelerates bone loss[5].
  Although the optimal treatment of osteoporosis remains 
controversial, as suggested by Verhaeghe et al[5], the most 
logical approach is to combine an antiresorptive agent to 
reverse the increased bone remodeling and an agent that 
stimulates osteblastic proliferation so that bone formation 
accrues more rapidly. Among the antireorptive agents 
available today, hormone replacement therapy (HRT) is 
perhaps the most effective treatment, as it has been shown 
to both reduce the rate of bone loss[6] and decrease the 
risk of fracture, including hip fracture[7]. However, not all 
the patients are willing to initiate this treatment due to 
a number of undesirable side effects and increased risk 
of endometrial and breast cancer[8-10] associated with 
prolonged use of estrogen therapy.
  The estrogen-like compounds of plant origin, such as 
soy isoflavones, have been characterized as naturally 
occurring selective estrogen receptor modulators with 
similar beneficial effects to raloxifene on bone[8,11]. The 
relationships between soybean isoflavones and bone tissue 
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have been studied for less than decade. Data from several 
animal studies have demonstrated that soy isoflavones 
had bone-conserving effects in the retention of bone mass 
following ovariectomy[6]. A possible role for soy isoflavones 
in modifying human bone mass has been suggested by bone 
et al[1]. They found that soy protein supplements enriched 
in isoflavones attenuated bone loss in postmenopausal and 
perimenopausal women. Some in vitro studies have suggested 
that isoflavones had biphasic effects, bone formation[1,12] and 
bone resorption[10]. Epidemiological studies indicate that 
women who have high soy food consumption have a lower 
risk of osteoporosis than women who consume a typical 
Western diet[13-15]. Consequently, many menopausal women 
use phytoestrogens to maintain their bone mass because 
they are unlikely to cause the undesirable effects associated 
with steroid hormones[16]. However, the random control trials 
on the effect of soy isoflavones on osteoporosis is conflicting, 
which may be due to the different content of soy isoflavones 
intake, trail duration and sample size. Therefore, the effects 
of soy isoflavones on osteoporosis remain unclear. This 
review of relevant meta-analysis aimed to clarify the effect 
of soy isoflavones on prevention of osteoporosis, and the 
effective dosage of soy isoflavones and its duration.
2. Materials and methods
2.1. Study selection
  Random control trials that investigated the association of 
soy isoflavones and osteoporosis were included in the meta-
analysis. Trials had to be original data from randomized 
controlled trials (RCTs) regarding association between soy 
isoflavones and osteoporosis. Randomizations by clusters 
or individuals were acceptable. We used no language or 
publication status restrictions. 
2.2. Inclusion and exclusion criteria
  Studies were included for systematic review if they met 
all of the following criteria: 1) included participants of 
menopausal (peri- or/and postmenopausal) women; 2) 
evaluated intervention of soy supplements containing 
isoflavones and clearly described ispflavone dose; 3) 
contained at least one relevant pair-wise comparison 
of intervention arms (i.e., soy isoflavone supplements 
vs. placebo, or both plus a non-estrogen add-on), and 
placebo used did not contain isoflavone or estrogen and was 
identical or similar in appearance and taste to comparative 
soy isoflavone supplements; 4) reported outcomes for the 
effects on at least one of the bone turnover markers. And 5) 
was a random control trial. Duplicated reports or subgroup 
analysis of the primary study were excluded.
 
2.3. Searching strategy for identification of studies
  We searched MEDLINE, EMBASE and the Chinese 
Biomedical Database. The data of the last search was 
October 2011. We designed a comprehensive and exhaustive 
search strategy for MEDLINE, EMBASE and the Chinese 
Biomedical Database databases to identify all relevant 
studies.
  To determine the studies for further assessment, two 
independent authors reviewed the titles, abstracts and 
keywords of all records retrieved to determine whether the 
studies were relevant to this review. Where the title and 
abstract did not provide adequate information, we assessed 
the full study and contact the authors of the study if 
additional information was required for further clarification. 
Disagreement was resolved by discussion. A total of 679 
articles were identified, 32 RCTs regarding soy isoflavones 
on osteoporosis were included. But 18 studies were excluded 
due to 16 on the cellular level or animal models and 2 
duplicate publications studies. Finally, we yielded 14 RCTs 
regarding soy isoflavones on osteoporosis. By contracting 
the related authors of two studies to supplement the missing 
data, data from one article were obtained, and others 
were not response or failure to contact. Two independent 
reviewers independently extract data.
2.4. Statistical analysis
  The RevMan software was used for all of the statistical 
analysis. We would analyze measures using weighted mean 
difference (WMD) and the 95% confidence interval (CI) in the 
analysis. The heterogeneity was tested with a Q-statistics 
with P-values < 0.05, and its possible sources were assessed 
by subgroup analysis as described below. A random-effect 
model was applied to obtain summary ORs and their 95% CI. 
The Egger’s regression asymmetry test was taken to evaluate 
publication bias (P<0.1 was considered representative of 
statistically significant publication bias). Subgroup analysis 
and meta-regressions were performed to investigate 
possible factors that might relate to varying effects of soy 
isoflavones on each bone markers across trials, on the basis 
of menopausal status, supplement type, isoflavone dose and 
intervention duration. A cut point of 75 mg/day of isoflavone 
dosage was used, a daily isoflavone intake of up to 75 mg 
is considered safe by the Japan Food Safety Commission. 
In addition, meta-regression was used to analyze the 
association of pre-specified factors with varying effect of 
isoflavones on different bone turnover markers. a sensitivity 
analysis was performed to explore robustness of the results.
3. Results
  A total of 19 trials were included in this meta-analysis are 
summarized in Table 1. Data for follow-up durations were 
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ranged from 1 month to 2 years. In the included studies, 
participants in the comparison group had similar physical 
activity patterns and habitual dietary intakes soy isoflavones, 
calcium, and vitamin D. Most of the studies were designed 
to maintain the participants’ usual diets, lifestyles and body 
weights. No serious adverse events were reported in the 
included studies.
  Table 2 showed the correlation between BMD and soy 
isoflavones intake. The random effects model revealed 
that daily ingestion of soy isoflavones for 1 month to 2 
years significantly increased BMD by 54% (95 CI: 13% to 
94%, P<0.001) compared with placebo (Figure 1). Of the 8 
Table 1
Characteristics of selected random control trials in the meta-analysis.
Study
Sample
(Intervention/
Control)
County Duration Participants Intervention Control Outcome
Wong 2009[17] 135/136 USA    2 years Peri   80 or 120 mg SI /d Placebo tablets BMD
Kenny 2009[18] 32/33 USA    1 year Post 105 mg SI tablets/d Placebo tablets BMD
Brink 2008[19] 45/46 France   1 year Post   90 mg 98.9% pure Ge /d in 
capsules
Placebo capsules BAP, DPD
Marini 2007[20] 198/191 Italy    2 years post   54 mg 98% pure Ge /d Placebo capsules BMD,BAP, DPD
Shao 2007[21] 30/30 China    6 months post   90 mg SI  capsule/d Placebo capsules BMD,BAP
Wu 2005[22] 34/34 Japan  12 months post   47 mg SI capsule/d Placebo capsules BMD, BAP, DPD
Ye 2006[23] 30/30 China    6 months post   84 or 126 mg SI capsule/d Placebo capsules BMD, DPD
Brooks 2004[24] 13/15 Canada    4 months post   41.9 mg Ge flour/d Placebo capsules DPD, BAP
Harkness 2004[25] 19/19 USA    1 year post 110 mg SI capsules/d Placebo capsules BMD
Kreijkamp-kaspers 
2004[26]
88/87 Netherlands    1 year post   99 mg SI capsules/d Placebo capsules BAP
Nikander 2004[27] 28/28 Finland    6 months post 114 SI capsules/d Placebo capsules DPD
Dalais 2003[28] 38/40 Australia    3 months post   69 mg SI capsules/d Placebo capsules DPD
Uesugi 2002[29] 12/11 Japan    1 month Peri   38.4 mg SI capsules/d Placebo capsules DPD
Yamori 2002[30] 20/20 Brazil 2.5 months post   22.7 mg SI scapsules/d Placebo capsules DPD
Ge: genistein; SI: soy isoflavones; BMD: bone mineral density (mg/cm2); DPD: urine deoxypyridinoline (nmol/mmol creatinine, unless specified); 
BAP: serum bone alkaline phosphatase (U/L, unless specified).
Study of subgroup Experimental Control Weiqht Std. mean dfference
IV, Random,95% CI
Std. mean difference 
IV, Random, 95%, CIMean SD Total Mean SD Total
Harkness 2004 0.890 0.030   19 0.880 0.020 19   10.0%   0.38(-0.26, 1.03)
Kenny 2009 1.106 0.085   32 1.086 0.103 33   11.2%   0.21(-0.28,0.70)
Marni 2007 0.850 0.080 198 0.830 0.100 191   13.0% 0.22(0.02,0.42)
Shao 2007 0.879 0.070   30 0.544 0.050   30     6.6% 5.44(4.31,6.56)
Wong 2009a 1.115 0.090 135 1.100 0.084 134   12.8%   0.17(-0.07,0.41)
Wong 2009b 1.121 0.093 134 1.100 0.084 134   12.8%   0.24(-0.00,0.48)
Wu 2005 0.996 0.105   34 0.994 0.089   34   11.3%   0.02(-0.46,0.50)
Ye 2006a 0.904 0.149   30 0.851 0.102   30   11.1%   0.41(-0.10,0.92)
Ye 2006b 0.841 0.108   30 0.851 0.102   30   11.1% -0.09(-0.60,0.41)
Total (95% CI) 642  635 100.0% 0.54(0.13,0.94)
Heterogeneity: Tau2=0.32; Chi2=85.18, df=8 (P<0.000 01); I2=91%
Test for overall effect: Z=2.60 (P=0.009)
-1      -0.5         0        0.5         1
Favours experimental Favours control
Figure 1. Effects of soy isoflavones on BMD (%). 
Mean difference, mean percentage changes (%) of BMD from baseline for soy isoflavones minus that for placebo.
Study of subgroup Experimental Control Weiqht Std. mean dfference
IV, Random,95% CI
Std. mean difference 
IV, Random, 95%, CIMean SD Total Mean SD Total
Brink 2008 28.50 10.50   45 25.90 12.60   46   15.0%     0.22(-0.19, 0.63)
Kenny 2009 24.70   8.80   32 26.80   8.60   33   13.2%  -0.24(-0.73,0.25)
Marni 2007 79.00   8.50 198 91.20 27.40 191   20.5%    -0.60(-0.81,-0.40)
Shao 2007 51.28 12.36   30 58.72 11.62   30   12.5%     -6.61(-1.13,-0.09)
Wu 2005 28.50   6.08   34 29.55   9.59   34   13.4%   -0.13(-0.61,0.35)
Ye 2006a 15.35   1.55   30 15.97   2.03   30   12.7%   -0.34(-0.85,0.17)
Ye2006b 15.97   1.74   30 15.97   2.03   30   12.7%     0.02(-0.46,0.50)
Total (95% CI) 399 394 100.0%     0.00(-0.51,0.51)
Heterogeneity: Tau2=0.08; Chi2=17.21, df=6 (P<0.009); I2=65%   -0.26(-0.53,0.01)
Test for overall effect: Z=1.89 (P=0.06)
-1      -0.5         0        0.5         1
Favours experimental Favours control
Figure 2. Effects of soy isoflavones on serum BAP (%). 
Mean difference, mean percentage changes (%) of urine BAD from baseline for soy isoflavones minus that for placebo.
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included trials, 8 trials resulted in positive mean difference 
in percentage change from baseline between isoflavone and 
placebo arms. The combined percentage change of urine 
BAD from baseline for soy isoflavones and placebo were 
decreased by 26% (53% to -1%). Additionally, for urine 
DPD, soy isoflavones decreased DPD from baseline by 23% 
(2% to 44%).
  Results of subgroup analysis of the effects of isoflavones 
on BMD and DPD based on the four pre-specified factors 
(menopausal status, supplement type, isoflavone dose, and 
intervention duration) are showed in Table 2 and Table 3. 
Using random effects model, the effect of isoflavones on BMD 
regarding menopausal status and isoflavone dose revealed 
higher WMD changes were found in postmenopausal women 
and isoflavone dose above 75 mg/d. Subgroup analysis of 
trials with menopausal status, supplement type, isoflavone 
dose and intervention duration that used soy isoflavone 
extracts resulted in significant different overall effect of DPD 
using by random effects model. The meta regression analysis 
did not show the menopause status, supplement type, 
isoflavone dose and intervention duration were significantly 
associated with the varying effects of isoflavones on BMD 
and DPD across included trails.
  The funnel plots did not indicated obvious publication 
bias. The sensitivity analysis did not result in significantly 
different overall effect of soy isoflavones on BMD, BAP and 
DPD after excluding trails with small sample, <6 months 
intervention duration and isoflavone dose ≤75 mg/d. 
4. Discussion
  The present meta-analysis found that soy isoflavones 
significantly increased the bone mineral density by 54% 
and decreased the bone resorption marker urinary DPD by 
23% compared to baseline in women. Sensitivity analysis 
Study of subgroup Experimental Control Weiqht Std. mean dfference
IV, Random,95% CI
Std. mean difference 
IV, Random, 95%, CIMean SD Total Mean SD Total
Brink 2008 15.00 5.00 45 15.60 5.20   46   18.8%   -0.12(-0.53, 0.29)
Brooks 2008   8.98 1.19   13   9.32 1.30   15     7.0%   -0.26(-1.01,0.48)
Dalais 2003 14.48 1.34   38 14.19 1.04   40   16.7%     0.24(-0.21,0.69)
Uesugi 2002   9.80 1.20   12   9.80 0.80   11     6.0%     0.00(-0.82,0.82)
Wu 2005   6.98 1.22   34   7.35 2.04   34   15.1%   -0.22(-0.69,0.26)
Yamori 2002   4.80 1.50   20   5.90 2.50   20     9.5%   -0.52(-1.15,0.11)
Ye 2006a   8.35 1.82   30   9.52 2.39   30   13.3%   -0.54(-1.06,-0.03)
Ye 2006b   8.23 2.19   30   9.52 2.39   30   13.3%   -0.56(-1.07,-0.04)
Total (95% CI) 222 226 100.0%   -0.23(-0.44,-0.02)
Heterogeneity: Tau2=0.02; Chi2=8.65, df=7 (P<0.28); I2=19%  
Test for overall effect: Z=2.14 (P=0.03)
-1      -0.5          0         0.5         1
Favours experimental Favours control
Table 2
Subgroup analysis of the effects of soy isoflavones on BMD (%)
Variables Trials Sample size P value for heterogeneity 
Fixed effect model
WMD 95% CI (%)
Menopausal status Perimenopausal 1 269/268 - 0.20 0.03, 0.37
Postmenopausal 6 423/416 0.001 0.77   0.1, 1.43
Isoflavone dose ≤75 mg/d 1 34/34 - 0.19 0.01, 0.37
>75 mg/d 6 658/650 <0.001 0.75 0.16, 1.34
Table 3
Subgroup analysis of the effects of soy isoflavones on urine DPD (%).
Variables Trials Sample size P value for heterogeneity
Fixed effect model
WMD 95% CI (%)
Menopausal status Perimenopausal 1 34/34 -   0.00 -0.82, 0.82
Postmenopausal 7 216/220 0.21 -0.25   -0.48, -0.02
Supplement type Isoflavone extracts 5 250/254 0.11 -0.30   -0.53, -0.07
Soy foods with isoflavones 3 179/179 0.61 -0.13 -0.62, 0.36
Isoflavone dose ≤75 mg/d 3 133/134 0.30 -0.37    -0.67, -0.07
>75 mg/d 5 117/120 0.35 -0.11 -0.38, 0.17
Intervention duration ≤6 months 5 250/254 0.53 -0.30    -0.53, -0.07
>6 months 3 179/179 0.13 -0.13 -0.62, 0.36
Figure 3. Effects of soy isoflavones on urine DPD (%).
Mean difference, mean percentage changes (%) of urine DPD from baseline for soy isoflavones minus that for placebo.
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indicated that the effect of soy isoflavones on BMD and 
DPD was robust. The postmenopausal women experience 
a sharp decrease in estrogen concentration that could lead 
to an increase rate of bone remodeling, and the increase 
bone remodeling is associated with both decreased BMD 
and increased risk of fracture[1,31,32]. Therefore, our meta-
analysis showed that soy isoflavone supplements might be 
associated to increased BMD and decrease risk of fracture in 
menopausal women.
  Our meta-analysis showed the BMD could be increased by 
54% in women with supplement isoflavones. The mechanism 
mediating the improvement of BMD by soy isoflavones is 
not well understood, but it may be a result of their chemical 
and biological similarity to mammalian estrogens, which are 
known to increase BMD in menopausal women[1,31]. Previous 
study showed the magnitude of significant effect of soy 
isoflavone extracts in increasing lumbar spine BMD by 20.3 mg/cm2,
and Ma et al[33] described in their meta-analysis a subgroup 
of several RCT testing isolated soy protein resulted in a 
significant increase in spine BMD by 21.3 (95% CI: 3-39.7 
mg/cm2). This result is consistent with ours, which indicated 
that soy isoflavones ingested either alone in extracted form 
or as constituent parts of isolated soy protein beneficially 
increase BMD in women.
  The The directions of the overall effect of soy isoflavone 
supplements on urine DPD and results of subgroup analyses 
on the basis of menopausal status were consistent with 
those demonstrated in a previous meta-analysis[33]. These 
indicated that soy isoflavone supplements, especially 
when ingested in extract form and when ingested by 
postmenopausal women, exert significant effects in 
decreasing the bone resorption marker DPD. Our meta-
analysis has more completely and more precisely clarified 
the effect of soy isoflavones on DPD by including additional 
studies and limiting the combining outcomes of percentage 
change from baseline. We observed differences in effects 
on DPD between subgroups on bases of menopause status 
supplement type, isoflavone dose and intervention duration, 
which can be explained the limited numbers of RCTs in each 
subgroup could limit the statistic power. Further studies 
are needed to clarify the particular subgroups, duration, 
dose and menopause status and intervention duration that 
may increase or decrease the magnitude of the effects of soy 
isoflavone supplements on DPD.
  There were several limitations of this meta-analysis. 
Firstly, there is existence of the significant heterogeneity in 
the effects of soy isoflavone supplement on BMD, urine DPD 
and serum BAP.
  on urine DPD, and some heterogeneity still existed after 
performing the subgroup analysis, suggesting that other 
factors should have been taken into account in the analysis. 
The heterogeneity of results across trials, which could be 
explained, might also be induced by differences in habitual, 
dietary intake of soy isoflavones, chemical forms and 
proportions of individual soy isoflavones. Another limitation 
was that meta-regressions analyzing each pre-specified 
factors did not reveal these factors to be associated with the 
various effects across trials, which could be explained the 
limited number of studies.
  In conclusion, the present meta-analysis revealed that soy 
isoflavone supplements significantly increased bone mineral 
density and decreased the bone resorption marker urinary 
DPD and showed no significant effect on bone formation 
markers serum BAP. The significant effect of soy isoflavones 
on BMD and urinary DPD was modified by menopausal 
status, supplement type, isoflavone dose and intervention 
duration. These findings may provide more information 
to the prevention of osteoporosis. Further studies also 
need to address factors relating to verify the effects of soy 
isoflavones on the bone turnover markers.
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